Search

Diagnosis in hematological diseases: morphology and flow cytometry

This SWG is active in disseminating knowledge on advances in the diagnosis and follow-up by morphology and multiparameter flow-cytometry of malignant and non-malignant hematological diseases. These include morphology, digital morphology, and flow-cytometry (mass, imaging, and spectral flow cytometry included).

Read more

Support opportunities

EHA Ranking for 2024 is now accessible via this link. EHA thrives on the support of the biomedical industry and the medical profession. The variety of opportunities available for industry range from educational activities to the EHA Congress.

Read more

EHA Innovation Grant

The call for applications is closed. The EHA Innovation Grant is intended to encourage and support the creation of consortia and the generation of preliminary data to facilitate applying for larger funding opportunities.

Read more

SWG Educational Activities

Past EHA (HOPE) Asia 2021 meeting 10-11 September 2021, Virutal

Speakers
Laane - Systematic review of literature on multiple myeloma EHA evidence-based “Guidelines for the use of patient-reported outcomes in adult patients with hematological malignancies” in progress - Systematic review of literature…

Read more

Is CBTH for me?

CBTH provides the development of computational biology skills for scholars who want to build successful careers in hematology research.

Read more

Freelance Event / Project Manager Congress (ZZP)

Hematologic diseases afflict millions of Europeans each year. The European Hematology Association (EHA), located in The Hague (Netherlands), is a non-profit professional association serving clinicians and researchers with an active interest in hematology in Europe and beyond.

Read more

Highlights from the SWG

EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.

Read more

Transfusion

The aim of this SWG is to strengthen and invigorate European research in transfusion, to foster new networks and collaborations, with the ultimate goal of optomisingtransfusion practice in Europe based on scientific evidence.

Read more